Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Position Lifted by New York State Common Retirement Fund

New York State Common Retirement Fund raised its stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 0.4% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 222,864 shares of the company’s stock after purchasing an additional 918 shares during the period. New York State Common Retirement Fund owned 0.48% of Mirum Pharmaceuticals worth $6,579,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of the stock. Wetzel Investment Advisors Inc. bought a new stake in shares of Mirum Pharmaceuticals in the 4th quarter valued at approximately $41,000. Knights of Columbus Asset Advisors LLC increased its stake in Mirum Pharmaceuticals by 101.6% during the fourth quarter. Knights of Columbus Asset Advisors LLC now owns 116,644 shares of the company’s stock valued at $3,443,000 after purchasing an additional 58,773 shares during the last quarter. Genworth Financial Inc bought a new stake in Mirum Pharmaceuticals during the fourth quarter valued at $385,000. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Mirum Pharmaceuticals by 74.3% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,601 shares of the company’s stock worth $254,000 after purchasing an additional 3,667 shares during the period. Finally, Arizona State Retirement System lifted its position in shares of Mirum Pharmaceuticals by 19.5% in the 4th quarter. Arizona State Retirement System now owns 8,413 shares of the company’s stock worth $248,000 after buying an additional 1,375 shares during the last quarter.

Mirum Pharmaceuticals Stock Performance

Shares of MIRM opened at $25.84 on Friday. The firm has a market capitalization of $1.22 billion, a PE ratio of -6.51 and a beta of 1.13. The company has a quick ratio of 4.19, a current ratio of 4.45 and a debt-to-equity ratio of 1.23. The firm has a 50-day moving average price of $26.16 and a 200 day moving average price of $28.20. Mirum Pharmaceuticals, Inc. has a 52-week low of $23.14 and a 52-week high of $35.56.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its quarterly earnings data on Wednesday, February 28th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.32). Mirum Pharmaceuticals had a negative net margin of 86.33% and a negative return on equity of 66.24%. The company had revenue of $69.55 million during the quarter, compared to the consensus estimate of $66.73 million. On average, sell-side analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.29 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on MIRM. JMP Securities increased their price objective on shares of Mirum Pharmaceuticals from $69.00 to $72.00 and gave the stock an “outperform” rating in a research note on Thursday, March 14th. HC Wainwright reiterated a “buy” rating and set a $58.00 price target on shares of Mirum Pharmaceuticals in a research report on Tuesday, April 2nd. Stifel Nicolaus assumed coverage on Mirum Pharmaceuticals in a research report on Wednesday, April 17th. They set a “buy” rating and a $48.00 price objective for the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $35.00 target price on shares of Mirum Pharmaceuticals in a research report on Thursday, February 29th. Finally, SVB Leerink reduced their price target on shares of Mirum Pharmaceuticals from $44.00 to $43.00 and set an “outperform” rating for the company in a report on Monday, March 18th. Eight research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Buy” and an average price target of $51.70.

Insider Activity at Mirum Pharmaceuticals

In related news, CFO Eric Bjerkholt bought 2,000 shares of the firm’s stock in a transaction on Monday, March 18th. The stock was purchased at an average price of $25.80 per share, with a total value of $51,600.00. Following the completion of the transaction, the chief financial officer now directly owns 12,000 shares of the company’s stock, valued at $309,600. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, COO Peter Radovich sold 4,303 shares of Mirum Pharmaceuticals stock in a transaction dated Monday, March 25th. The stock was sold at an average price of $25.80, for a total value of $111,017.40. Following the transaction, the chief operating officer now directly owns 29,013 shares in the company, valued at $748,535.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Eric Bjerkholt acquired 2,000 shares of the business’s stock in a transaction that occurred on Monday, March 18th. The shares were acquired at an average cost of $25.80 per share, with a total value of $51,600.00. Following the transaction, the chief financial officer now directly owns 12,000 shares in the company, valued at approximately $309,600. The disclosure for this purchase can be found here. 24.06% of the stock is owned by company insiders.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.